Browse Studies — Arctuva

Phase 2

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be …

Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)+1 more

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT06153173

Histiocytic Disorder Follow-up Study

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-…

HistiocytosisLangerhans Cell HistiocytosisErdheim-Chester Disease+3 more

Estimated

~$10 – $750

University of Alabama at BirminghamNCT05915208

International Rare Histiocytic Disorders Registry (IRHDR)

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease…

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more

Estimated

~$10 – $750

The Hospital for Sick ChildrenNCT02285582

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorder…

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more

Estimated

~$10 – $7,500

Carl AllenNCT04079179